Beetler Danielle J, Bruno Katelyn A, Di Florio Damian N, Douglass Erika J, Shrestha Swikriti, Tschöpe Carsten, Cunningham Madeleine W, Krejčí Jan, Bienertová-Vašků Julie, Pankuweit Sabine, McNamara Dennis M, Jeon Eun-Seok, van Linthout Sophie, Blauwet Lori A, Cooper Leslie T, Fairweather DeLisa
Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, FL, United States.
Center for Clinical and Translational Science, Mayo Clinic, Rochester, MN, United States.
Front Cardiovasc Med. 2023 Jan 18;9:1073814. doi: 10.3389/fcvm.2022.1073814. eCollection 2022.
The goal of this study was to determine whether sex and age differences exist for soluble ST2 (sST2) for several cardiovascular diseases (CVDs).
We examined sST2 levels using an ELISA kit for myocarditis ( = 303), cardiomyopathy ( = 293), coronary artery disease (CAD) ( = 239), myocardial infarct (MI) ( = 159), and congestive heart failure (CHF) ( = 286) and compared them to controls that did not have CVDs ( = 234).
Myocarditis occurred in this study in relatively young patients around age 40 while the other CVDs occurred more often in older individuals around age 60. We observed a sex difference in sST2 by age only in myocarditis patients (men aged 38, women 46, = 0.0002), but not for other CVDs. Sera sST2 levels were significantly elevated compared to age-matched controls for all CVDs: myocarditis ( ≤ 0.0001), cardiomyopathy ( = 0.0009), CAD ( = 0.03), MI ( = 0.034), and CHF ( < 0.0001) driven by elevated sST2 levels in females for all CVDs except myocarditis, which was elevated in both females ( = 0.002) and males ( ≤ 0.0001). Sex differences in sST2 levels were found for myocarditis and cardiomyopathy but no other CVDs and were higher in males (myocarditis = 0.0035; cardiomyopathy = 0.0047). sST2 levels were higher in women with myocarditis over 50 years of age compared to men ( = 0.0004) or women under 50 years of age ( = 0.015). In cardiomyopathy and MI patients, men over 50 had significantly higher levels of sST2 than women ( = 0.012 and = 0.043, respectively) but sex and age differences were not detected in other CVDs. However, women with cardiomyopathy that experienced early menopause had higher sST2 levels than those who underwent menopause at a natural age range ( = 0.02).
We found that sex and age differences in sera sST2 exist for myocarditis, cardiomyopathy, and MI, but were not observed in other CVDs including CAD and CHF. These initial findings in patients with self-reported CVDs indicate that more research is needed into sex and age differences in sST2 levels in individual CVDs.
本研究的目的是确定可溶性ST2(sST2)在几种心血管疾病(CVD)中是否存在性别和年龄差异。
我们使用酶联免疫吸附测定试剂盒检测了心肌炎(n = 303)、心肌病(n = 293)、冠状动脉疾病(CAD)(n = 239)、心肌梗死(MI)(n = 159)和充血性心力衰竭(CHF)(n = 286)患者的sST2水平,并将其与无CVD的对照组(n = 234)进行比较。
本研究中心肌炎多发生在40岁左右的相对年轻患者中,而其他CVD更多发生在60岁左右的老年个体中。我们仅在心肌炎患者中观察到按年龄划分的sST2性别差异(男性38岁,女性46岁,P = 0.0002),其他CVD则未观察到。与年龄匹配的对照组相比,所有CVD患者的血清sST2水平均显著升高:心肌炎(P≤0.0001)、心肌病(P = 0.0009)、CAD(P = 0.03)、MI(P = 0.034)和CHF(P<0.0001),除心肌炎外,所有CVD中女性sST2水平升高导致差异,心肌炎中女性(P = 0.002)和男性(P≤0.0001)sST2水平均升高。在心肌炎和心肌病中发现了sST2水平的性别差异,其他CVD未发现,男性sST2水平更高(心肌炎P = 0.0035;心肌病P = 0.0047)。50岁以上心肌炎女性的sST2水平高于男性(P = 0.0004)或50岁以下女性(P = 0.015)。在心肌病和MI患者中,50岁以上男性的sST2水平显著高于女性(分别为P = 0.012和P = 0.043),但在其他CVD中未检测到性别和年龄差异。然而,过早绝经的心肌病女性的sST2水平高于自然绝经年龄范围的女性(P = 0.02)。
我们发现心肌炎、心肌病和MI患者血清sST2存在性别和年龄差异,但在包括CAD和CHF在内的其他CVD中未观察到。这些自我报告患有CVD的患者的初步研究结果表明,需要对个体CVD中sST2水平的性别和年龄差异进行更多研究。